Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Vaccinations01:51

Vaccinations

44.0K
Overview
44.0K
Development of Immunocompetence01:22

Development of Immunocompetence

283
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
283

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Maternal and Newborn Group B <i>Streptococcus</i> Serology in the United States and South Africa.

Open forum infectious diseases·2026
Same author

Randomized Phase 3 Comparison of a 2-Dose and 3-Dose Regimen of a Detoxified Toxin A/B <i>Clostridioides difficile</i> Vaccine in Adults 50 Years and Older.

Open forum infectious diseases·2026
Same author

Rezvilutamide in combination with androgen deprivation therapy (ADT) with or without docetaxel in the neoadjuvant treatment of oligometastatic prostate cancer (REDOOM): study protocol for an open-label, parallel-cohort, multicentre clinical study.

BMJ open·2026
Same author

Long-term safety of the Pfizer-BioNTech COVID-19 vaccine: Results from the HERO-together study.

Respiratory medicine·2026
Same author

Establishment of a Neonatal Natural Transmission Model for CMV Vaccine Development.

The Journal of infectious diseases·2026
Same author

Bivalent RSVpreF Subunit Vaccine Safety and Immunogenicity in Seropositive 2-<18 Year Olds.

Vaccines·2026

Related Experiment Video

Updated: Jun 3, 2025

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay
09:14

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay

Published on: January 26, 2019

10.7K

A Statistical Model to Predict Protection Against Infant Respiratory Syncytial Virus Disease Through Maternal

Bing Cai1, Yili Chen2, Yasmeen Agosti3

  • 1Vaccine Research and Development, Pfizer Inc., Collegeville, PA 19426, USA.

Vaccines
|January 8, 2025
PubMed
Summary

Maternal immunization against respiratory syncytial virus (RSV) protects infants. Statistical models accurately predicted infant vaccine efficacy by considering maternal antibodies, transfer, decay, and infant-specific risks.

Keywords:
RSVairway resistanceinfantsmodelingvaccine efficacyviral infection

More Related Videos

Intranasal Immunization and Milk Collection in Studies of Maternal Immunization in New Zealand White Rabbits Oryctolagus cuniculus
13:00

Intranasal Immunization and Milk Collection in Studies of Maternal Immunization in New Zealand White Rabbits Oryctolagus cuniculus

Published on: July 31, 2021

3.5K
An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection
09:01

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection

Published on: December 10, 2013

7.9K

Related Experiment Videos

Last Updated: Jun 3, 2025

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay
09:14

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay

Published on: January 26, 2019

10.7K
Intranasal Immunization and Milk Collection in Studies of Maternal Immunization in New Zealand White Rabbits Oryctolagus cuniculus
13:00

Intranasal Immunization and Milk Collection in Studies of Maternal Immunization in New Zealand White Rabbits Oryctolagus cuniculus

Published on: July 31, 2021

3.5K
An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection
09:01

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection

Published on: December 10, 2013

7.9K

Area of Science:

  • Immunology
  • Vaccinology
  • Pediatrics

Background:

  • Respiratory syncytial virus (RSV) is a major global cause of infant respiratory illness.
  • Maternal immunization is a strategy to protect infants, leveraging transplacental antibody transfer.
  • Estimating protection correlates for maternal RSV vaccines is complex due to immunobiology and disease factors.

Purpose of the Study:

  • To develop statistical models for predicting infant vaccine efficacy (VE) after maternal immunization.
  • To identify key factors influencing infant protection from maternal vaccination.

Main Methods:

  • Developed predictive statistical models incorporating maternal antibody titers, transplacental transfer, antibody decay rates, and RSV disease incidence.
  • Included infant-specific factors like airway diameter and resistance in the models.

Main Results:

  • Model predictions closely matched observed vaccine efficacy outcomes in maternal RSV prefusion F vaccine trials.
  • Integration of infant lower respiratory tract disease risk was crucial for accurate VE modeling.

Conclusions:

  • The developed models successfully predicted the vaccine efficacy of maternal RSV vaccines.
  • These models offer a valuable tool for predicting clinical trial outcomes for other vaccines where maternal antibodies are protective.